New hope for kids with rare kidney disease

NCT ID NCT06994845

Recruiting now Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

Summary

This study is testing an oral drug called iptacopan in children and teenagers with a rare kidney disease called IgA nephropathy (IgAN). The main goal is to see if the drug safely reduces protein in the urine, which is a key sign of kidney damage. About 34 participants, aged 2 to under 18, will take the drug for one year to measure its effects.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PRIMARY IMMUNOGLOBULIN A NEPHROPATHY (IGAN) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-••••

Locations

Childrens Hospital Colorado
RECRUITING

Aurora, Colorado, 80045, United States

Contact

Contact Phone: •••-•••-•••• Email: •••••@•••••
Childrens Hospital of Philadelphia
NOT_YET_RECRUITING

Philadelphia, Pennsylvania, 19104, United States

Contact
Novartis Investigative Site
RECRUITING

Nedlands, Western Australia, 6009, Australia
Novartis Investigative Site
RECRUITING

Hangzhou, Zhejiang, 310052, China
Novartis Investigative Site
RECRUITING

Beijing, 100034, China
Novartis Investigative Site
RECRUITING

Beersheba, 8457108, Israel
Novartis Investigative Site
RECRUITING

Haifa, 3109601, Israel
Novartis Investigative Site
RECRUITING

Jerusalem, 9103102, Israel
Novartis Investigative Site
RECRUITING

Petah Tikva, 4920235, Israel
Novartis Investigative Site
RECRUITING

Kurume, Fukuoka, 830-0011, Japan
Novartis Investigative Site
RECRUITING

Ohtsu, Shiga, 5202192, Japan
Novartis Investigative Site
RECRUITING

Fuchū, Tokyo, 1838561, Japan
Prim Childrens Hosp Inv Pharm
RECRUITING

Salt Lake City, Utah, 84113, United States

Contact Email: •••••@•••••

Contact
University of Florida Shands Division
NOT_YET_RECRUITING

Gainesville, Florida, 32610, United States

Contact

Conditions

Explore the condition pages connected to this study.

PRIMARY IMMUNOGLOBULIN A NEPHROPATHY (IGAN)